China Universal Asset Management Company’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$318K Sell
17,695
-1,793
-9% -$27.7K 0.02% 310
2026
Q1
$271K Buy
19,488
+1,593
+9% +$22.4K 0.02% 326
2025
Q4
$216K Buy
17,895
+2,265
+14% +$30.8K 0.02% 338
2025
Q3
$212K Sell
15,630
-2,274
-13% -$21.4K 0.02% 333
2025
Q2
$115K Buy
17,904
+716
+4% +$3.48K 0.01% 354
2025
Q1
$60.8K Buy
17,188
+2,653
+18% +$9.44K 0.01% 400
2024
Q4
$54.9K Buy
14,535
+1,441
+11% +$6.78K 0.01% 446
2024
Q3
$42.4K Buy
13,094
+5,104
+64% +$11.5K ﹤0.01% 394
2024
Q2
$15.2K Sell
7,990
-5,014
-39% -$9.72K ﹤0.01% 396
2024
Q1
$36.9K Buy
13,004
+5,189
+66% +$67.9K ﹤0.01% 421
2023
Q4
$115K Buy
7,815
+6,085
+352% +$93.3K 0.02% 267
2023
Q3
$31.7K Buy
1,730
+850
+97% +$18K 0.01% 262
2023
Q2
$19K Sell
880
-17
-2% -$459 0.01% 272
2023
Q1
$26.3K Buy
897
+224
+33% +$7.78K 0.01% 196
2022
Q4
$24.9K Buy
+673
New +$23.9K 0.01% 165

Other funds holding AMLX

China Universal Asset Management Company's AMLX Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Amylyx Pharmaceuticals (AMLX) stake by 9.2% in Q2 2026, selling an estimated $27.7K and leaving 17,695 shares worth $318K. The position accounts for 0.02% of the portfolio, ranked #310.

China Universal Asset Management Company first reported a position in AMLX in Q4 2022 and has held it in 15 quarters since. 27 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • China Universal Asset Management Company held 17,695 shares of Amylyx Pharmaceuticals worth $318K as of Q2 2026.
  • China Universal Asset Management Company sold 1,793 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $27.7K.
  • Amylyx Pharmaceuticals made up 0.02% of China Universal Asset Management Company's portfolio in Q2 2026, its #310 holding.
  • China Universal Asset Management Company first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • 27 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.